Gates: Best Bets Hiv cure & Resevoir Consortium The BMGF

New Post Public Reply Private Reply Replies (0) Message Board
My69z
1,235
Gates: Best Bets Hiv cure & Resevoir Consortium

The BMGF formed Frontiers Jan. 2020.
A 2-step program:

1)Develop a Sickle Cell delivery.
2)Then test it for Hiv delivery suppression.

Below is excerpts from the Director of Frontiers, Dr. McCune describing this in Jan. 2020:

"Using state-of-the-art assays, it is hoped that circulating nonviral biomarkers for the rebound-competent reservoir will be discovered in the nonhuman primate, crossvalidated in the human, and assessed for their ability to define the size and quality of the rebound-competent reservoir while on antiretroviral therapy (ART), and the time to viral rebound once ART is discontinued."

( Dr. J did a 2023 43 person LL/ART stop trial )

"....and to simultaneously launch the HIV Reservoirs Consortium. "

"....and with an anticipated “youth bulge” and increasing resistance to ART,1 an uncontrolled epidemic may possibly even grow."

(Our just released Multi-Drug Resistance paper )
(WHO says 30m people are on ART)
(MDR alone could be a company maker)

"....Technically, it has been hard to clarify these unknowns because the viral reservoir resides in tissues (e.g., lymphoid organs, the central nervous system, and the gut) that cannot be easily or comprehensively accessed in PLHIV."

( Dr. Sacha has papers on all these )

"...Meanwhile, even though the NIH and organizations such as amfAR have devoted considerable resources to academic laboratories to discover and develop cures for HIV and to more deeply study the biology of the rebound-competent reservoir, ..."

( Dr. Sacha again )

"...In aggregate, the motivating factors and resources required to bring curative interventions for HIV to resource-limited parts of the world would appear to require new models for discovery, innovation, and risk-sharing partnership."

(Main reason always said GF/ViiV(GSK) liscensing)

"...envisioning two interlocking areas of focus: one that would explore the Current Best Bets for HIV cure and another that would create an HIV Reservoirs Consortium to understand the biology of the rebound-competent reservoir and circulating nonviral biomarkers of it."

(No better Best Bet for Hiv sterilize than Dr. Sacha)

"....Indeed, we view the extension of promising ex vivo gene therapies for sickle cell disease to people in need in sub-Saharan Africa as an imperative; this exercise may also serve as a pathfinder for analogous in vivo gene therapy approaches for an HIV cure."

( "may also serve" --LL is direct to disease & works)

"...Modeling of the epidemic in sub-Saharan Africa, where transmission rates remain high, suggests that an optimal curative intervention should not only suppress (or eliminate) the rebound-competent reservoir within affected individuals but also prevent infection upon re-exposure to virus."

(Dr. Sacha is .."or eliminate"..Dr. McCune is suppress)

"...include interventions that provide a durable effect without repeated administration, for example, extended provision of multiple bNAbs or of eCD4, and/or the induction of a long-lasting and effective antiviral immune response. Given the examples of the “Berlin patient” and the “London patient” as well as intriguing preliminary data with directed CCR5 knockout in peripheral blood cells, interventions ablating this focus might also be pursued."

(100% match to now Berlin LATCH & LL)

"...To introduce such modifications in vivo, it will be necessary to design vectors that can carry the appropriate editing systems to selected target cells after percutaneous (e.g., intravenous or intramuscular) administration."

(Our AAV Vector patent application comes to mind)

"...given commercial opportunities in areas like oncology, it is inevitable that even more options will surface in the future."

(Dr. J -- Oncology is our priority)

"...We have also considered it important to initiate—sooner than later—a vigorous discussion about the ultimate implementation of curative interventions for HIV and sickle cell disease into sub-Saharan Africa."

(Will Leronlimab be more than Hiv via GF/ViiV(GSK)?

"...to be maximally effective and practical, interventions to cure HIV must be designed to suppress the rebound-competent reservoir of HIV over a relatively long period of time, for example, by engaging an immune response that destroys and/or prevents viral spread from cells harboring rebound-competent viral genomes."

(Our ART+bNab+LL results comes to mind)

"...Going into this work, a bottom-line reality must be accepted: the aspirational goal of safe, effective, and widely accessible in vivo gene therapy is daunting and may not be doable."

(That's Sickle Cell development. We know LL works)

"...However, its utility for HIV cure depends on the success of cure designs for sickle cell disease and the continued ability to leverage commercial interest."

(We know LL works)

"...However, its utility for HIV cure depends on the success of cure designs for sickle cell disease and the continued ability to leverage commercial interest."

(We know LL works)

"...We are also working to cement partnerships with multinational pharmaceutical companies that have the expertise, resources, and motivation to bring such therapies into the field and through to commercialization."

(GF/ViiV(GSK) for Hiv?)
(LL for Hiv & Sickle cell ?)

* All of the authors are supported by the Bill & Melinda Gates Foundation.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10112459/

*The HIV Reservoir Consortium is a collaboration of researchers working to find a cure for HIV by identifying and targeting reservoirs of the virus.

*Goals
1) Discover biomarkers that indicate the size and quality of the HIV reservoir
2) Develop strategies to eliminate or control the virus
3) Design clinical trials to test new therapies
______
After reading my short version of this long article, do 1 more thing:

Jan. 2020 Frontiers said 8-10 years from trials.
Contracted the Sickle Cell & Hiv work to Novartis. Check Novartis site & Clinicaltrials.com for Hiv.

Nothing there.

Feb. 21st, 2025 Bill and Melinda Gates Foundation gave Dr. Sacha $1m grant related to resevoir:
https://stocktwits.com/Bio4/message/605280087

https://investorshangout.com/post/view?id=6746404

Bill Gates now says: --- A cure is on the way

We sterilize Hiv.
We are "Best Bet".

Leronlimab is cure.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Virse Revolutionizes Creative Production with AI Canvas

Updated Category News Views 156

A New Era in Creative Workflows These days, the design world is getting a major shake-up thanks to Virse's innovative AI-driven workspace. Based out of Dover, this new system isn't just about boosting tech for the sake of it; it's about making creative production a symphony rather than a cacophony. And, let me tell ya, any time I've loaded up on coffee to prep for a brand...

Continue Reading
MPLX Reports Q3 2026 Results with 12.5% Distribution Hike

Updated Category News Views 34

Another Distribution Hike: 12.5% Bump in Q3 Man, MPLX is at it again, boosting that quarterly distribution by a hefty 12.5%. That's three years running now, marking it up to $4.84 per unit on an annualized basis. In an industry where reliability sometimes feels like a relic, this kind of consistency is a sweet serenade to any income-focused investor's ears. "MPLX is...

Continue Reading
Newcomers, Veterans Elevate NYSE's Tokenization Efforts

Updated Category News Views 100

Breaking New Ground at the NYSE When the bell rings at the NYSE these days, it's not just marking the start of another trading session. It's the sound of change clanging its way onto Wall Street. On November 3, 2026, the NYSE threw its hat deeper into the tokenization ring, a game-changer perhaps. They've roped in some big guns—Securitize, tZERO, Broadridge Financial...

Continue Reading
Lupin Launches HIV Treatment, Secures 180-Day Exclusivity

Updated Category News Views 18

Lupin's Market Move: A Big Step in HIV Treatment There's a fresh gust blowing in the pharmaceutical skies today, as Lupin leaps ahead with the launch of their Raltegravir Tablets in the U.S. The company just bagged FDA approval, putting them on the front lines with a high-stake 180-day exclusivity period for their generic version. For investors keeping tabs on pharma...

Continue Reading
Canton Fair Showcases Cutting-Edge Healthcare Tech 2026

Updated Category News Views 41

Innovation Steals the Show in Guangzhou In a world where tech evolution rarely takes a breather, the 140th Canton Fair's Intelligent Healthcare Zone is like a breath of fresh air. Picture it: a whole arena pulsing with futuristic healthcare gizmos from October 31 to November 4, 2026—it's as if tomorrow swung by for a sneak peek. The event brings together everything from...

Continue Reading
Yunji Rolls Out AI Robots at EquipHotel Paris 2026

Updated Category News Views 90

AI Takes Center Stage in Hospitality When someone mentions a new revolution in hospitality, I usually roll my eyes. But this time, Yunji Technology (HKEX: 02670) is bringing something to the table that's hard to ignore. They’re out in full force at EquipHotel Paris 2026, flaunting their AI-powered collection of service bots with the kind of confidence that says, 'We're...

Continue Reading
Reju Partners with Six Mills to Advance Textile Regeneration

Updated Category News Views 203

Big Moves in Textile Regeneration Now here's a move that's got the fabric world buzzing: Reju, the scrappy textile-to-textile regenerative powerhouse, is teaming up with six mills spread across Europe and the U.S. They’re setting the stage to crank up their polyester recycling game and flood the market with sustainable, eco-friendly fabrics. It's a bold step toward...

Continue Reading
Himel's Latest: Powering Industry and Homes Alike

Updated Category News Views 46

Switching Gears: Himel's New Electrical Frontiers Ah, the humming of motors, the click of switches—it's the backbone of any decent industrial setup or modern home today. Himel isn't messing around when it comes to staying on top of these evolving electrical needs, both in gritty industrial settings and our cozy living rooms. This time, they're taking a serious crack at...

Continue Reading
XPENG Eyes South Korea Entry with Industry Veteran

Updated Category News Views 142

A Veteran's Task in a New Territory Piling onto its international ambitions, XPENG has roped in Lee Man-sik, a seasoned auto industry professional, to break into South Korea. South Korea isn’t just another market—it’s one of the toughest stages for the automotive industry. The customers there are sharp, with a keen eye for tech and quality. So XPENG, trading under...

Continue Reading
Samsung Biologics Hits 'Negligible' ESG Risk Milestone

Updated Category News Views 26

Samsung Biologics Achieves a Low-Risk Triumph You gotta hand it to Samsung Biologics for hitting a 'Negligible Risk' rating. Their latest score? A cool 9.0. That’s like walking into the pharmaceuticals room and getting a standing ovation. It's no small feat—climbing up from a 'Low Risk' rating to the top tier in Morningstar Sustainalytics' playbook. For us spectating...

Continue Reading

Top 5 Most Recently Viewed Articles

Deutsche Bank's Optimism for Monster Beverage's Future Growth

Updated Category News Views 287

Positive Outlook for Monster Beverage (NASDAQ:MNST) Deutsche Bank has reiterated its optimistic outlook on Monster Beverage, maintaining a Buy rating with a consistent price target of $61. This affirmation comes as the company is poised to announce its third-quarter earnings, which are expected to meet market forecasts, albeit with slightly cautious revenue expectations....

Continue Reading
Ideal Living Unveils Smart AquaTru Carafe for Clean Water Access

Updated Category News Views 308

Introducing AquaTru Carafe Smart: A New Era of Water Purification Ideal Living has taken a pioneering step in ensuring that everyone can have access to pure, clean water with the launch of the AquaTru Carafe Smart. This innovative product is not just a water purifier; it’s a smart device designed to keep you informed about your water quality, ensuring safer drinking...

Continue Reading
Interface's Q4 Earnings: A Closer Look at TILE's Performance

Updated Category News Views 192

Analyzing Interface's Q4 Earnings Interface (NASDAQ:TILE) rolled out its Q4 earnings report on February 24, 2026, and let me tell you, there’s buzz in the air. They posted an EPS of $0.49, beating expectations by a solid 22.5%. Now, that’s the kind of surprise that can make a market jump. They also got revenue up by $14.38 million since this time last year—people...

Continue Reading
Unveiling Innovations at Telematics & Connected Mobility 2025

Updated Category News Views 277

Exploring the Future at Telematics & Connected Mobility 2025 Gurtam is excited to announce its flagship event, Telematics & Connected Mobility 2025, taking place in early September. This two-day event will gather a diverse group of participants, including fleet operators, telematics service providers, industry experts, and innovative hardware manufacturers. The goal is to...

Continue Reading
Codexis Provides New Grants to Enhance Talent Acquisition

Updated Category News Views 114

Codexis Announces New Employment Inducement Grants Today, Codexis, Inc. (NASDAQ: CDXS), a prominent player in the field of enzymatic solutions, made headlines with its announcement regarding new employment inducement grants. This move illustrates Codexis' commitment to recruiting top-tier talent, essential for their continuous growth and innovation. Details of the...

Continue Reading